Global Exporter & Bulk Supplier of Carflieva 60 mg Injection

🌍 Introduction

Are you in search of a highly reliable and globally compliant exporter for Carflieva 60 mg Injection? At Ernest Oncology (a flagship division of Ernest Pharmaceutical Pvt. Ltd.), we specialize in the secure, temperature-controlled, and efficient distribution of advanced oncology therapeutics. We are a premier supplier of Carfilzomib 60 mg injections to hospitals, specialty pharmacies, and pharmaceutical wholesalers across the USA, UK, Australia, and South Africa.

🔬 1. Product Overview: Carflieva 60 mg Injection

Carflieva 60 mg Injection contains Carfilzomib, a second-generation selective proteasome inhibitor designed for high-efficacy treatment in hematological malignancies.

• Composition: Carfilzomib 60 mg (as a sterile lyophilized powder)

• Therapeutic Class: Proteasome Inhibitor / Antineoplastic Agent

• Formulation Type: Single-dose vial for intravenous (IV) infusion

• Storage: Store under refrigeration at 2°C to 8°C (36°F to 46°F).

⚙️ 2. Mechanism of Action

Carflieva utilizes a sophisticated pathway to combat malignant cells:

• Epoxomicin Derivative: Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome.

• Selective Inhibition: By blocking the proteasome's ability to degrade polyubiquitinated proteins, it leads to an excessive buildup of proteins within the cell.

• Cell Cycle Arrest: This buildup triggers significant cellular stress, leading to cell cycle arrest and apoptosis (programmed cell death), particularly in myeloma cells which are highly dependent on proteasome function.

🏥 3. Therapeutic Indications

Carflieva 60 mg Injection is clinically indicated for:

• Relapsed or Refractory Multiple Myeloma: Used as a monotherapy for patients who have received at least two prior therapies (including bortezomib and an immunomodulatory agent).

• Combination Therapy: Often prescribed in combination with Dexamethasone or Lenalidomide plus Dexamethasone for patients with relapsed or refractory multiple myeloma.

⚠️ 4. Administration & Safety Guidelines

• Route: Must be administered only by Intravenous (IV) Infusion over 10 or 30 minutes, depending on the dosage regimen.

• Hydration: Adequate hydration is critical before and after administration to reduce the risk of renal toxicity and Tumor Lysis Syndrome (TLS).

• Side Effects: Common reactions include fatigue, anemia, nausea, thrombocytopenia, and dyspnea.

• Cardiac Warning: Patients should be monitored for cardiac complications, including heart failure and myocardial infarction.